Darizmetinib
Darizmetinib (HRX215) is a selective MKK4 inhibitor whose mechanism involves enhancing MKK7-JNK1 signaling to activate transcription factors like ATF2 and ELK1, thereby promoting hepatocyte proliferation. This activity supports its research use in studying liver regeneration and related disease models in both cellular and preclinical contexts.
Product Specifications
CAS Number
2369583-33-3
Product Name Alternative
Antiviral, MAP2K, HRX-0215, HRX215
Field of Research
Cell Biology, Immunology & Inflammation, Signal Transduction
Purity
98.03% (May vary between batches)
Solubility
DMSO:180 mg/mL (393.49 mM) ; H2O:< 1 mg/mL (insoluble or slightly soluble)
Smiles
O=C (C1=NNC2=NC=C (C=C21) C=3C=CN=CC3) C4=CC=C (F) C (NS (=O) (=O) CCC) =C4F
Molecular Formula
C21H17F2N5O3S
Molecular Weight
457.45
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
E3697Hu-01 48 Well
Human Metastasis-associated protein MTA1, MTA1 ELISA KIT
Sign In for Pricing
View Details E3697Hu-02 96 Well
Human Metastasis-associated protein MTA1, MTA1 ELISA KIT
Sign In for Pricing
View Details E3697Hu-03 5x 96 Tests
Human Metastasis-associated protein MTA1, MTA1 ELISA KIT
Sign In for Pricing
View Details E3697Hu-04 10x 96 Tests
Human Metastasis-associated protein MTA1, MTA1 ELISA KIT
Sign In for Pricing
View Details 
sc-400887-ACT 20 µg
Mast Cell Tryptase CRISPR Activation Plasmid (h)
Sign In for Pricing
View Details 